These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31319379)

  • 41. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
    Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
    J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of endocrine active and clinically silent corticotropic adenomas by in situ hybridization.
    Lloyd RV; Fields K; Jin L; Horvath E; Kovacs K
    Am J Pathol; 1990 Aug; 137(2):479-88. PubMed ID: 2167013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease.
    Granger N; de Fornel P; Devauchelle P; Segond S; Delisle F; Rosenberg D
    J Vet Intern Med; 2005; 19(1):23-8. PubMed ID: 15715043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells.
    Sugiyama A; Kageyama K; Murasawa S; Ishigame N; Niioka K; Daimon M
    Pituitary; 2015 Aug; 18(4):542-53. PubMed ID: 25280813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. E2F1-mediated human POMC expression in ectopic Cushing's syndrome.
    Araki T; Liu NA; Tone Y; Cuevas-Ramos D; Heltsley R; Tone M; Melmed S
    Endocr Relat Cancer; 2016 Nov; 23(11):857-870. PubMed ID: 27935805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
    Gentilin E; Tagliati F; Terzolo M; Zoli M; Lapparelli M; Minoia M; Ambrosio MR; Degli Uberti EC; Zatelli MC
    J Endocrinol; 2013 Sep; 218(3):275-85. PubMed ID: 23814013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation.
    Occhi G; Regazzo D; Albiger NM; Ceccato F; Ferasin S; Scanarini M; Denaro L; Cosma C; Plebani M; Cassarino MF; Mantovani G; Stalla GK; Pecori Giraldi F; Paez-Pareda M; Scaroni C
    Endocrinology; 2014 Sep; 155(9):3538-49. PubMed ID: 24926820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.
    Asari Y; Kageyama K; Sugiyama A; Kogawa H; Niioka K; Daimon M
    Endocr J; 2019 Jun; 66(6):515-522. PubMed ID: 30880293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
    Chen J; Jian X; Deng S; Ma Z; Shou X; Shen Y; Zhang Q; Song Z; Li Z; Peng H; Peng C; Chen M; Luo C; Zhao D; Ye Z; Shen M; Zhang Y; Zhou J; Fahira A; Wang Y; Li S; Zhang Z; Ye H; Li Y; Shen J; Chen H; Tang F; Yao Z; Shi Z; Chen C; Xie L; Wang Y; Fu C; Mao Y; Zhou L; Gao D; Yan H; Zhao Y; Huang C; Shi Y
    Nat Commun; 2018 Aug; 9(1):3171. PubMed ID: 30093687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired processing of proopiomelanocortin in corticotroph macroadenomas.
    Gibson S; Ray DW; Crosby SR; Dornan TL; Jennings AM; Bevan JS; Davis JR; White A
    J Clin Endocrinol Metab; 1996 Feb; 81(2):497-502. PubMed ID: 8636257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids.
    Gatto F; Feelders RA; van der Pas R; van Koetsveld P; Bruzzone E; Arvigo M; Dogan F; Lamberts S; Ferone D; Hofland L
    J Endocrinol; 2020 Apr; 245(1):101-113. PubMed ID: 32027601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.
    Hinojosa-Amaya JM; Lam-Chung CE; Cuevas-Ramos D
    Front Endocrinol (Lausanne); 2021; 12():657382. PubMed ID: 33986726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
    Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
    J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
    Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
    J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome.
    de Keyzer Y; Lenne F; Auzan C; Jégou S; René P; Vaudry H; Kuhn JM; Luton JP; Clauser E; Bertagna X
    J Clin Invest; 1996 Mar; 97(5):1311-8. PubMed ID: 8636444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of antisense DNA on POMC mRNA and ACTH levels in cultured human corticotroph adenoma cells.
    Woloschak M; Post K; Roberts JL
    J Endocrinol Invest; 1994 Nov; 17(10):817-9. PubMed ID: 7699217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.
    Pecori Giraldi F; Cassarino MF; Sesta A; Lasio G; Losa M
    Neuroendocrinology; 2023; 113(6):606-614. PubMed ID: 36791678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of genes associated with the corticotroph phenotype in bronchial carcinoid tumors.
    Pascual-Le Tallec L; Dulmet E; Bertagna X; de Keyzer Y
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5015-22. PubMed ID: 12414866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells.
    Oliveira HA; Bueno AC; Pugliesi RS; da Silva Júnior RMP; de Castro M; Martins CS
    J Endocrinol Invest; 2022 May; 45(5):999-1009. PubMed ID: 34988938
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
    Rak B; Maksymowicz M; Pękul M; Zieliński G
    Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.